Salbutamol sulfate, guaifenesin.
Each 5 mL (1 teaspoonful) syrup contains: Salbutamol (as Sulfate), USP 1 mg and Guaifenesin 50 mg.
Pharmacology: Pharmacodynamics & Pharmacokinetics: Salbutamol is a selective Beta-2 adrenoceptor agonist. At therapeutic doses, it acts on the Beta-2 adrenoceptor of bronchial muscle with little or no action on the Beta-1 adrenoceptor of cardiac muscle.
Guaifenesin can make the viscous mucus of the respiratory pathways more fluid and therefore facilitates expectoration and reduces cough.
In the presence of excessive mucus, adequate pulmonary ventilation cannot be achieved simply by relieving bronchospasm. It is necessary to remove mucus obstruction. The combination of salbutamol and guaifenesin is designed to relieve respiratory obstruction and improve pulmonary ventilation.
Relief of productive and wheezing cough associated with bronchitis, pneumonia, asthma and other respiratory infections.
Adults and children over 12 years old: 2-4 teaspoonful (10-20 mL).
7-12 years old: 2 teaspoonful (10 mL).
2-6 years old: 1-2 teaspoonful (5-10 mL).
To be taken orally two to three times a day or as prescribed by the physician.
The preferred antidote for overdosage with salbutamol is a cardioselective, beta-blocking agent. However, beta-blocking drugs should be used with caution in patients with history of bronchospasm. Hypokalemia may occur following overdose with salbutamol, serum potassium levels should be monitored.
Contraindicated in patients with a history of hypersensitivity to any of its components.
Salbutamol and non-selective beta-blocking drugs, such as propranolol should not usually be prescribed together. Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis.
Potentially, serious hypokalemia may result from Beta-2 agonist therapy mainly from parenteral and nebulized administration.
Pregnancy: Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Lactation: As Salbutamol is probably secreted in human breast milk. Its use in nursing mother is not recommended unless the expected benefit outweigh any potential risk. It is not known whether Salbutamol in breast milk has harmful effect on the neonate. Long term treatment with salbutamol plus guaifenesin Expectorant Syrup increase the risk of dental carries, it is important that adequate dental hygiene is maintained.
May cause a fine tremor of skeletal muscle, usually the hands are most obviously affected. This effect is dose related and is common to all β-adrenergic stimulants.
Occasionally, headache has been reported. Few patients experience a feeling of tension, this is also due to the effects on skeletal muscle and not to the direct CNS stimulation.
Very rare reports of transient muscle cramps.
Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse have been reported very rarely.
Serious hypokalemia may result from Beta-2 agonist, hyperactivity has been reported rarely in children. Side effects associated with guaifenesin are rare.
Use of salbutamol and other Beta-2 agonists with corticosteroids, diuretics, or xanthines increases the risk of hypokalemia, and monitoring of potassium concentrations is recommended in severe asthma, where such combination is common.
Store at temperatures not exceeding 30°C.
R05CA10 - combinations ; Belongs to the class of expectorants. Used in the treatment of wet cough.
Asfrenon-GF syr
120 mL x 1's (P175/bottle);60 mL x 1's (P101/bottle)
Sign Out
